A non-canonical striatopallidal "Go" pathway that supports motor control.

Go pathway Npas1 arkypallidal axon collaterals axonal copy basal ganglia bridging collaterals direct pathway efference copy globus pallidus medium spiny neurons motor control striatopallidal striatum

Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
11 Feb 2023
Historique:
pubmed: 18 2 2023
medline: 18 2 2023
entrez: 17 2 2023
Statut: epublish

Résumé

In the classical model of the basal ganglia, direct pathway striatal projection neurons (dSPNs) send projections to the substantia nigra (SNr) and entopeduncular nucleus to regulate motor function. Recent studies have re-established that dSPNs also possess "bridging" collaterals within the globus pallidus (GPe), yet the significance of these collaterals for behavior is unknown. Here we use in vivo optical and chemogenetic tools combined with deep learning approaches to dissect the roles of bridging collaterals in motor function. We find that dSPNs projecting to the SNr send synchronous motor-related information to the GPe via axon collaterals. Inhibition of native activity in dSPN GPe terminals impairs motor activity and function via regulation of pallidostriatal Npas1 neurons. We propose a model by which dSPN GPe collaterals ("striatopallidal Go pathway") act in concert with the canonical terminals in the SNr to support motor control by inhibiting Npas1 signals going back to the striatum.

Identifiants

pubmed: 36798372
doi: 10.21203/rs.3.rs-2524816/v1
pmc: PMC9934763
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIMH NIH HHS
ID : T32 MH018870
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH093672
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH086466
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS069777
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH124858
Pays : United States
Organisme : NINDS NIH HHS
ID : R56 NS069777
Pays : United States

Commentaires et corrections

Type : UpdateIn

Auteurs

Marie A Labouesse (MA)

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.
Current address: Department of Health, Sciences and Technology, ETH Zurich, and Zurich Neuroscience Center, 8057 Zurich, Switzerland.

Arturo Torres-Herraez (A)

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.
Equal second-author contribution.

Muhammad O Chohan (MO)

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Division of Child and Adolescent Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA.
Equal second-author contribution.

Joseph Villarin (J)

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.
Equal second-author contribution.

Julia Greenwald (J)

Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.

Xiaoxiao Sun (X)

Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.

Mysarah Zahran (M)

Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.
Barnard College, Columbia University, New York, NY 10027, USA.

Alice Tang (A)

Columbia College, Columbia University, New York, NY 10027, USA.

Sherry Lam (S)

Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD 21224, USA.

Jeremy Veenstra-VanderWeele (J)

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Division of Child and Adolescent Psychiatry, New York State Psychiatric Institute, New York, NY 10032, USA.

Clay Lacefield (C)

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.

Jordi Bonaventura (J)

Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD 21224, USA.
Departament de Patologia i Terapèutica Experimental, Institut de Neurociències, Universitat de Barcelona, L'Hospitalet de Llobregat, Catalonia.

Michael Michaelides (M)

Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD 21224, USA.
Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore MD 21205, USA.

C Savio Chan (CS)

Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

Ofer Yizhar (O)

Departments of Brain Sciences and Molecular Neuroscience, Weizmann Institute of Science, Rehovot 76100, Israel.

Christoph Kellendonk (C)

Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA.
Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Lead contact: Christoph Kellendonk.

Classifications MeSH